Lapsed Dec 7, 2025 on the fee record · Medium confidence
20-year base term ends Jun 30, 2029
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,889,133), so the cap could be lower.
First maintenance fee unpaid; grace period ended.
Held by Denovo Biopharma LLC
Filed Oct 16, 2019 as application 16/654,318 · Granted Dec 7, 2021
Base term, 20 years from filing
Today
Lapsed Dec 7, 2025
2009
2029
Clock starts
Jun 30, 2009
Jun 30, 2009
No longer in force
Dec 7, 2025
Dec 7, 2025
Granted
Dec 7, 2021
Dec 7, 2021
Term would have run to
Jun 30, 2029
Jun 30, 2029
base term
after the term ends
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,320,738, US 9,889,133, to Jun 30, 2029. The term already ends on or before that date, so the cap shortened nothing.
0 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Jun 30, 2029: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 30, 2009, when application PCT/US2009/049322, the earliest non-provisional in its chain, was filed (this one was filed Oct 16, 2019) | Jun 30, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,320,738, US 9,889,133) | resolves to Jun 30, 2029, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 1 maintenance fees paid | lapsed Dec 7, 2025 | High confidence |
| Computed term end | The steps above, in order | Dec 7, 2025 | Medium confidence |
This family
| Application PCT/US2009/049322 | PCT application no patent term | no patent term |
| US 9,320,738 | In force Mar 2030 | Mar 2030 |
| US 9,889,133 | Lapsed on the fee record Feb 2026 | Feb 2026 |
| US 10,449,194 | In force Jun 2029 | Jun 2029 |
| US 11,191,764 | this patent Dec 2025 | Dec 2025 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 16, 2020 Reel 53233, frame 419 | Tocagen Inc. | Denovo Biopharma LLC | Assignment of Assignor's Interest |
| Oct 21, 2020 Reel 54133, frame 61 | Gruber, Harry E.; Jolly, Douglas J.; Olmstead, Kay | Tocagen Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,320,738, US 9,889,133, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2021 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.